T2 Biosystems Strikes Deal with CRG for Debt-to-Equity Conversion

T2 Biosystems, a pioneer in rapid sepsis detection, shakes hands with CRG to swap $15 million in debt for equity. This move, pending shareholder approval, aims to bolster T2 Biosystems' financial standing. The company's CEO, John Sperzel, expresses gratitude for CRG's ongoing support. This debt conversion follows previous amendments to the CRG Term Loan Agreement, showcasing a strategic financial maneuver to fortify the company's position. T2 Biosystems, known for its innovative T2MR technology, is on a mission to revolutionize patient care and cost reduction in healthcare. With a robust product lineup and a promising pipeline, T2 Biosystems is poised for growth and success in the medical technology landscape.